| Official American thoracic society/centers for disease control and prevention/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible … P Nahid, SE Dorman, N Alipanah, PM Barry, JL Brozek, A Cattamanchi, ... Clinical infectious diseases 63 (7), e147-e195, 2016 | 1559 | 2016 |
| An official ATS statement: hepatotoxicity of antituberculosis therapy JJ Saukkonen, DL Cohn, RM Jasmer, S Schenker, JA Jereb, CM Nolan, ... American journal of respiratory and critical care medicine 174 (8), 935-952, 2006 | 1520 | 2006 |
| Therapeutic drug monitoring in the treatment of tuberculosis CA Peloquin Drugs 62, 2169-2183, 2002 | 562 | 2002 |
| Therapeutic drug monitoring in the treatment of tuberculosis: an update A Alsultan, CA Peloquin Drugs 74, 839-854, 2014 | 464 | 2014 |
| Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline P Nahid, SR Mase, GB Migliori, G Sotgiu, GH Bothamley, JL Brozek, ... American journal of respiratory and critical care medicine 200 (10), e93-e142, 2019 | 435 | 2019 |
| Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials WJ Burman, K Gallicano, C Peloquin Clinical pharmacokinetics 40, 327-341, 2001 | 435 | 2001 |
| Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis JL Johnson, DJ Hadad, WH Boom, CL Daley, CA Peloquin, KD Eisenach, ... The International Journal of Tuberculosis and Lung Disease 10 (6), 605-612, 2006 | 348 | 2006 |
| Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases CA Peloquin, SE Berning, AT Nitta, PM Simone, M Goble, GA Huitt, ... Clinical Infectious Diseases 38 (11), 1538-1544, 2004 | 319 | 2004 |
| Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery JC Sung, DJ Padilla, L Garcia-Contreras, JL VerBerkmoes, D Durbin, ... Pharmaceutical research 26, 1847-1855, 2009 | 288 | 2009 |
| Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana S Chideya, CA Winston, CA Peloquin, WZ Bradford, PC Hopewell, ... Clinical infectious diseases 48 (12), 1685-1694, 2009 | 281 | 2009 |
| Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide CA Peloquin, GS Jaresko, CL Yong, AC Keung, AE Bulpitt, RW Jelliffe Antimicrobial agents and chemotherapy 41 (12), 2670-2679, 1997 | 270 | 1997 |
| Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis M Weiner, D Benator, W Burman, CA Peloquin, A Khan, A Vernon, ... Clinical infectious diseases 40 (10), 1481-1491, 2005 | 267 | 2005 |
| Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine M Weiner, W Burman, A Vernon, D Benator, CA Peloquin, A Khan, S Weis, ... American journal of respiratory and critical care medicine 167 (10), 1341-1347, 2003 | 266 | 2003 |
| Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model IM Rosenthal, M Zhang, KN Williams, CA Peloquin, S Tyagi, AA Vernon, ... PLoS medicine 4 (12), e344, 2007 | 257 | 2007 |
| Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis CA Peloquin, DJ Hadad, LPD Molino, M Palaci, WH Boom, R Dietze, ... Antimicrobial agents and chemotherapy 52 (3), 852-857, 2008 | 236 | 2008 |
| Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis WJ Burman, K Gallicano, C Peloquin Clinical infectious diseases, 419-429, 1999 | 232 | 1999 |
| Low antituberculosis drug concentrations in patients with AIDS CA Peloquin, AT Nitta, WJ Burman, KF Brudney, JR Miranda-Massari, ... Annals of Pharmacotherapy 30 (9), 919-925, 1996 | 226 | 1996 |
| Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids CA Peloquin, R Namdar, MD Singleton, DE Nix Chest 115 (1), 12-18, 1999 | 224 | 1999 |
| Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model of tuberculosis R Tasneen, SY Li, CA Peloquin, D Taylor, KN Williams, K Andries, ... Antimicrobial agents and chemotherapy 55 (12), 5485-5492, 2011 | 221 | 2011 |
| Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response DE Nix, SD Goodwin, CA Peloquin, DL Rotella, JJ Schentag Antimicrobial Agents and Chemotherapy 35 (10), 1953-1959, 1991 | 216 | 1991 |
